HP
HealthInvest Partners Portfolio holdings
AUM $234M
1-Year Return
10.88%
This Quarter Return
+4.42%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$85.6M
AUM Growth
+$5.45M
(+6.8%)
Cap. Flow
+$1.32M
Cap. Flow
% of AUM
1.54%
Top 10 Holdings %
Top 10 Hldgs %
85.3%
Holding
14
New
3
Increased
1
Reduced
7
Closed
2
Top Buys
| 1 |
Cigna
CI
|
+$6.58M |
| 2 |
Waters Corp
WAT
|
+$6.45M |
| 3 |
Medtronic
MDT
|
+$6.39M |
| 4 |
McKesson
MCK
|
+$845K |
Top Sells
| 1 |
Cencora
COR
|
+$10.4M |
| 2 |
Gilead Sciences
GILD
|
+$1.7M |
| 3 |
Biogen
BIIB
|
+$1.44M |
| 4 |
ImmuCell
ICCC
|
+$1.34M |
| 5 |
Ligand Pharmaceuticals
LGND
|
+$1.13M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
McKesson
MCK
$87.4B
| $10.5M | 12.3% |
68,600
+5,500
| +9% | +$845K |
|
2
Elevance Health
ELV
$68.8B
| $10.5M | 12.24% |
55,200
| – | – |
|
3
Anika Therapeutics
ANIK
$126M
| $6.67M | 7.79% |
115,000
-10,000
| -8% | -$580K |
|
|
4
Cigna
CI
$78.1B
| $6.58M | 7.68% |
+35,200
| New | +$6.58M |
|
5
Charles River Laboratories
CRL
$7.43B
| $6.57M | 7.67% |
60,812
-9,400
| -13% | -$1.02M |
|
|
6
Ligand Pharmaceuticals
LGND
$3.22B
| $6.52M | 7.62% |
76,784
-13,305
| -15% | -$1.13M |
|
7
Pfizer
PFE
$137B
| $6.47M | 7.56% |
191,090
-24,769
| -11% | -$839K |
|
|
8
Waters Corp
WAT
$17.8B
| $6.45M | 7.53% |
+35,900
| New | +$6.45M |
|
|
9
Biogen
BIIB
$21.3B
| $6.39M | 7.46% |
20,400
-4,600
| -18% | -$1.44M |
|
10
Labcorp
LH
$22.8B
| $6.39M | 7.46% |
49,237
-4,074
| -8% | -$528K |
|
|
11
Medtronic
MDT
$122B
| $6.39M | 7.46% |
+82,100
| New | +$6.39M |
|
|
12
Gilead Sciences
GILD
$139B
| $6.21M | 7.25% |
76,600
-21,000
| -22% | -$1.7M |
|
|
13
Cencora
COR
$56.3B
| – | – |
-109,700
| Closed | -$10.4M |
|
|
14
ImmuCell
ICCC
$53.8M
| – | – |
-182,133
| Closed | -$1.34M |
|